Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nrx Pharmaceuticals Inc
(NQ:
NRXP
)
1.734
+0.004 (+0.24%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nrx Pharmaceuticals Inc
< Previous
1
2
3
Next >
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
August 15, 2024
Via
Get News
Topics
Regulatory Compliance
Retirement
Exposures
Legal
Pension
Regulatory
Alignment with FDA on Pediatric Study Plan and Accelerated Approval to Treat Bipolar Depression and Akathisia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
July 30, 2024
Via
Get News
Exposures
Product Safety
Accelerated Approval to Treat Bipolar Depression and Akathisia Could Yield Over $150 in Revenue Per Share; Planned HOPE Subsidiary Spinoff to Continue: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
July 29, 2024
Via
Get News
NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant’s Efficacy in Reducing Suicidality in Bipolar Depression at ASCP June 2024 Meeting: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
June 10, 2024
Via
Get News
First Oral Antidepressant Clinically Demonstrated to Reduce Suicidality in Bipolar Depression with Data Supporting Accelerated Approval Process: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
May 28, 2024
Via
Get News
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
August 15, 2024
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to...
Via
PRLog
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update
May 08, 2024
Via
ACCESSWIRE
Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plans to Seek Accelerated Approval for Bipolar Depression and Schizophrenia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
May 06, 2024
Via
Get News
InvestorNewsBreaks – NRx Pharmaceuticals Inc. Releases Pricing of Public Offering, Expected to Result in Estimated $2M
April 22, 2024
Via
Investor Brand Network
Exposures
Product Safety
New Data on Infection Avoidance and Development of pH Neutral Ketamine, for Intravenous and Subcutaneous Use: NRx Pharmaceuticals (Nasdaq: NRXP)
April 17, 2024
Via
Get News
Exposures
Product Safety
Successful Development of pH Neutral Ketamine, Potentially Enabling Both Intravenous and Subcutaneous Use; Trials Progressing for Suicide Drug Treatment After Strong Q4 Results: NRXP
April 15, 2024
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Planned Public Stock Dividend in Specialty Pharmaceutical Company Hope Therapeutics; Royalty Rights also Pledged to Shareholders for Valuable Ketamine Franchise: NRx Pharmaceuticals (Nasdaq: NRXP)
March 19, 2024
Via
Get News
Trial Endpoint Reached for First Suicidal Bipolar Depression, Chronic Pain and PTSD Drug; Agreement with Partners Can Provide up to $329 Million and Royalties: NRx Pharmaceuticals (Nasdaq: NRXP)
March 04, 2024
Via
Get News
Exposures
Product Safety
5 Biotech stocks tapping into unmet mental health treatment needs
December 20, 2023
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
Via
MarketBeat
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
December 04, 2023
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Featured in Virtual Coverage of Dawson James Small Cap Growth Conference
October 09, 2023
Via
Investor Brand Network
SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Investors to Contact the Firm
August 16, 2023
From
Kaskela Law LLC
Via
Business Wire
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
November 14, 2022
Via
ACCESSWIRE
NASDAQ:NRXP Long Term Investor Alert: Investigation over Possible Wrongdoing at NRx Pharmaceuticals, Inc.
May 16, 2022
San Diego, CA -- (SBWIRE) -- 05/16/2022 -- Certain directors of NRx Pharmaceuticals, Inc. are under investigation over possible breaches of fiduciary duties.
Via
SBWire
NRX PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of NRx Pharmaceuticals, Inc. - NRXP
May 05, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
NRX PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of NRx Pharmaceuticals, Inc. - NRXP
April 29, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
NRX PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of NRx Pharmaceuticals, Inc. - NRXP
April 09, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Final Deadline Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
March 21, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
NRX DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
March 18, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Deadline Monday Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
March 18, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)
March 18, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Deadline Monday Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
March 17, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
NASDAQ: NRXP Investor Notice: Deadline on March 21, 2022 in Lawsuit Against NRx Pharmaceuticals, Inc.
March 16, 2022
San Diego, CA -- (SBWIRE) -- 03/16/2022 -- A Deadline is coming up on March 21, 2022in the lawsuit for certain investors in NRx Pharmaceuticals, Inc. (NASDAQ: NRXP).
Via
SBWire
Deadline Monday Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
March 16, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Monday Deadline Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
March 15, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.